AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol

Androgen receptor signaling inhibitors (ARSI) are used to treat castration-resistant prostate cancer (CRPC) to stop a resurgence of androgen receptor (AR) signaling. Despite early success, patients on ARSIs eventually relapse, develop drug resistance, and succumb to the disease. Resistance may occur...

Descripción completa

Detalles Bibliográficos
Autores principales: Detlefsen, Andrea J., Mesaros, Clementina A., Duan, Ling, Penning, Trevor M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508215/
https://www.ncbi.nlm.nih.gov/pubmed/37772993
http://dx.doi.org/10.1158/2767-9764.CRC-23-0235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508215/
https://www.ncbi.nlm.nih.gov/pubmed/37772993
http://dx.doi.org/10.1158/2767-9764.CRC-23-0235

Ejemplares similares